Skip to main content
Article thumbnail
Location of Repository

APRIL is overexpressed in cancer: link with tumor progression

By Jérôme Moreaux, Jean-Luc Veyrune, John De Vos and Bernard Klein
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2662875
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). A meta-analysis of human embryonic stem cells transcriptome integrated into a webbased expression atlas. Stem Cells
    2. (1999). a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med
    3. (2000). A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.
    4. (2004). A: Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
    5. (2002). An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. Embo J
    6. (2008). APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa.
    7. (1998). APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.
    8. (2004). Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer genetics and cytogenetics
    9. (2006). B: The source of APRIL up-regulation in human solid tumor lesions.
    10. (2005). BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma.
    11. (2001). Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep
    12. (2005). Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res
    13. (2008). CA: APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early life bone marrow stromal cells. Blood
    14. (2006). CC: CNS viral infection diverts homing of antibodysecreting cells from lymphoid organs to the CNS.
    15. (2006). Chaganti RS: Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res
    16. (2004). Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA
    17. (2004). Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform.
    18. (2006). Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
    19. (2002). DF: Aberrant expression of Blymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood
    20. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature
    21. (2004). et al.: Expression of BLyS and Its Receptors in B-Cell Non-Hodgkin Lymphoma: Correlation With Disease Activity and Patient Outcome. Blood
    22. (2005). et al.: Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization.
    23. (2005). et al.: Identification of molecular apocrine breast tumours by microarray analysis. Oncogene
    24. (2005). et al.: Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med
    25. (2006). et al.: Molecular diagnosis of Burkitt's lymphoma.
    26. (2006). et al.: Selective activation of TACI by syndecan-2. Blood
    27. (2005). et al.: The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    28. (2005). et al.: The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood
    29. (2002). et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
    30. (2003). Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.
    31. (2006). Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell
    32. (2001). Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA
    33. (2006). Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res
    34. (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA
    35. (2006). Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology
    36. (2007). Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood
    37. (2001). Glypicans in growth control and cancer. Glycobiology
    38. (2004). Grimm MO: Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res
    39. (2006). Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene
    40. (2007). Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to
    41. (2003). JP: TWEPRIL; a fusion protein of TWEAK and APRIL. Biochem Pharmacol
    42. (2008). Jr: Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia
    43. (2002). Kovalszky I: Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol
    44. (2005). Medema JP: Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ
    45. (2003). MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC cancer
    46. (2002). Narayanasami U: Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer
    47. (2006). Neuronal and gliomaderived stem cell factor induces angiogenesis within the brain. Cancer Cell
    48. (2007). Neutrophilderived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood
    49. (2008). Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis.
    50. (2004). PM: Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res
    51. (2006). Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res
    52. (2002). R: BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol
    53. (2004). resistance to apoptosis of B-CLL through an autocrine pathway. Blood
    54. (2006). RJ: Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood
    55. (2008). Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas.
    56. (2004). SF: Gene expression profiling of gliomas strongly predicts survival. Cancer Res
    57. (2005). Sikic BI: Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res
    58. (2005). Sillevis Smitt PA: Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res
    59. (2006). SM: B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood
    60. (2000). Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet
    61. (2003). Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol
    62. (2001). Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood
    63. (2007). TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica
    64. (2008). TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood
    65. (2003). Tangye SG: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.
    66. (2004). Tarte K: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood
    67. (2004). Tsapis A: Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene
    68. (2005). Weichselbaum RR, et al.: Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res
    69. (1999). Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.